IL-13Rα2 UCAR-T

IL-13Rα2 UCAR-T is an allogeneic, "off-the-shelf" chimeric antigen receptor (CAR) T-cell therapy developed by the Second Affiliated Hospital of Soochow University for the treatment of recurrent glioma, specifically glioblastoma multiforme (GBM). The therapy targets Interleukin-13 receptor alpha 2 (IL-13Rα2), a tumor-associated antigen that is highly overexpressed in high-grade gliomas but has limited expression in normal brain tissue. As a universal CAR-T (UCAR-T) product, it is derived from healthy donor T cells rather than the patient's own cells. To minimize the risk of graft-versus-host disease (GvHD) and immune rejection by the recipient, gene-editing technologies (such as CRISPR/Cas9) are typically employed to disrupt the T-cell receptor (TCR) and potentially HLA molecules. This approach allows for immediate treatment availability and potentially lower manufacturing costs compared to autologous CAR-T therapies.

Other names

IL-13Rα2-targeted universal CAR-T cellsIL-13Rα2-targeted UCAR-TAllogeneic IL-13Rα2 CAR-T